Description
Background:
Mosunetuzumab is a humanized CD20 x CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. It can recognize and bind two different targets simultaneously, CD20 on tumor B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. Currently, Mosunetuzumab is being investigated in several combination therapies for Non-Hodgkins Lymphoma, Leukemia and Follicular Lymphoma.
Intended Use:
For Estimation of Mosunetuzumab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!